Childhood acute lymphoblastic leukemia: 12 years of experience, using a Berlin–Frankfurt–Münster approach, in a Greek center

References

• Conter V, Arico M, Basso G, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 2010;24:255–264.
   PubMed Web of Science ®Google Scholar
• Möricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010;24:265–284.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Stevenson KE, O’Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 2010;24:320–334.
   PubMed Web of Science ®Google Scholar
• Papadakis V, Panagiotou JP, Polychronopoulou-Androulakaki S, et al. Results of childhood acute lymphoblastic leukemia treatment in Greek patients using a BFM-based protocol. Haema 2003;6:208–216.
   Google Scholar
• ALL IC 2009 trial of the I-BFM Study Group, 2009.0 Available from: http://www.bfm-international.org.
   Google Scholar
• Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM90. German-Austrian-Swiss ALLBFM Study Group. Blood 2000;95: 3310–3322.
   Google Scholar
• Gustafsson G, Kreuger A, Clausen N, et al. Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non-high-risk patients: the Nordic experience of 2648 patients diagnosed between 1981 and 1996. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Acta Paediatr 1998;87:1151–1161.
   Google Scholar
• Igarashi S, Manabe A, Ohara A, et al. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol. J Clin Oncol 2005;23:6489–6498.
   PubMed Web of Science ®Google Scholar
• Eden TO, Pieters R, Richards S, et al. Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5,659 children. Br J Haematol 2010;149: 722–733.
   PubMed Web of Science ®Google Scholar
• Smith M, Arthur D, Cammita B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18–24.
   PubMed Web of Science ®Google Scholar
• Sutcliffe MJ, Shuster JJ, Sather HN, et al. High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI standard-risk B-precursor acute lymphoblastic leukemia: a Children's Oncology Group (COG) initiative. Leukemia 2005;19:734–740.
   PubMed Web of Science ®Google Scholar
• AIEOP-BFM 2009 Trial of the I-BFM Study Group, 2009. Available from: http://www.bfm-international.org.
   Google Scholar
• Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009;27:5168–5174.
   PubMed Web of Science ®Google Scholar
• Katsimpardi K, Papadakis V, Pangalis A, et al. Infections in a pediatric patient cohort with acute lymphoblastic leukaemia during the entire course of treatment. Support Care Cancer 2006;14: 277–284.
   PubMed Web of Science ®Google Scholar
• Bhojwani D, Pei D, Sandlund JT, et al. ETV6-RUNX1-positive childhood acute lymphoblastic leukemia:improved outcome with contemporary therapy. Leukemia 2012;26:265–270.
   PubMed Web of Science ®Google Scholar
• Papadhimitriou SI, Polychronopoulou S, Tsakiridou AA, et al. P16 inactivation associated with aggressive clinical course and fatal outcome in TEL-AML1-positive acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2005;27:675–677.
   PubMed Web of Science ®Google Scholar
• Kuchinskaya E, Heyman M, Nordgren A, et al. Interphase fluorescent in situ hybridization deletion analysis of the 9p21 region and prognosis in childhood acute lymphoblastic leukaemia (ALL): results from a prospective analysis of 519 Nordic patients treated according to the NOPHO-ALL 2000 protocol. Br J Haematol 2011;152: 615–622.
   PubMed Web of Science ®Google Scholar
• Dworzak MN, Froschl G, Printz D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002;99: 1952–1958.
   PubMed Web of Science ®Google Scholar